Drug Profile


Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine - Dendreon; Prostate cancer vaccine (APC-8015) - Dendreon; Provenge

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; T lymphocyte cell therapies; Tissue extracts
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 03 Jun 2017 Pharmacodynamics data from the phase II STAND, STRIDE and STAMP trials in Prostate cancer presented at the annual meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2017 Dendreon terminates a phase II trial in Prostate cancer (Metastatic disease) in USA (NCT01338012) prior to June 2017
  • 13 May 2017 Sub-group efficacy analysis data from a phase IV trial in Prostate cancer released by Dendreon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top